Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Galapagos   /   Morphosys-Galapagos, Therapeutic Antibodies

Aandeel Galapagos AEX:GLPG.NL, BE0003818359

Laatste koers (eur) Verschil Volume
25,380   +1,420   (+5,93%) Dagrange 24,000 - 25,380 146.795   Gem. (3M) 111,9K

Morphosys-Galapagos, Therapeutic Antibodies

Volgen
451 Posts
Pagina: «« 1 2 3 4 5 6 ... 23 »» | Laatste | Omlaag ↓
  1. aossa 26 februari 2009 11:04
    quote:

    parelduiker schreef:

    van de in november vorig jaar aangekondigde samenwerking met Morphosys (50/50 deal) mag ook het nodige verwacht worden,een prima partner voor Galapagos.

    Galapagos en MorphoSys gaan gezamenlijk antilichaam-medicijnen ontwikkelen voor bot- en gewrichtsziekten

    Combinatie van nieuwe medicijn targets en unieke technologieën om pijplijn van nieuwe antilichaam-medicijnen te creëren
    Uit het bericht van vandaag, zie:
    www.morphosys.com/en/news_investors/p...

    212.14.81.205/uploads/MOR-YE2008_IFRS...

    EXPECTED RESEARCH AND DEVELOPMENT
    • Validation of three targets together with Galapagos which might be the subject of therapeutic antibody programs in the future.

    ==========================
    flosz - 24 feb 09, 12:32

    Upcoming Conference Call
    02/26/2009 - Year End 2008 and Q4 Results

    MorphoSys will publish its Annual Financial Results 2008 on February 26, 2009 at 7:30 a.m. CET.
    MorphoSys will hold its Analyst and Press Conference in Frankfurt, Germany. Additionally, the Management Team of MorphoSys AG will host a conference call and audio webcast to present MorphoSys’s Annual Financial Results 2008 and provide an outlook for 2009.
    DATE: Thursday, 26th February 2009
    TIME: 14:00 p.m. CET
    DIAL IN No: +49 (0) 69 710491462 (listen-only)
    UK RESIDENTS: +44 (0) 1212 604860
    US RESIDENTS: +1 (1) 866 347 1957
    We request that you call the number above up to 10 minutes early to ensure a prompt start and a secure line.
    MorphoSys AG offers participants the opportunity to follow the presentation through a simultaneous slide presentation online.
    Slide presentation with sound: www.thomson-webcast.net/de/dispatchin...
    Slide presentation without sound for participants of the conference call
    A slide-synchronized audio replay of the conference will be available following the live event on www.morphosys.com
  3. flosz 1 maart 2009 19:36
    quote:

    aossa schreef:

    212.14.81.205/uploads/MOR-YE2008_IFRS...

    EXPECTED RESEARCH AND DEVELOPMENT
    • Validation of three targets together with Galapagos which might be the subject of therapeutic antibody programs in the future.

    As a result of the alliance signed with Galapagos in November
    2008, an initial set of three targets has been selected for
    validation through disease-specifi c in vitro and in vivo testing
    with antibodies provided by MorphoSys. If these studies
    are successful, the alliance will select antibody programs
    for preclinical and clinical development.

    GALAPAGOS
    In November 2008, MorphoSys AG and Galapagos NV announced
    the launch of a long-term co-development alliance
    aimed at discovering and developing antibody therapies
    based on novel modes of action in bone and joint disease, for
    the treatment of rheumatoid arthritis, osteoporosis and
    osteoarthritis.
    The alliance spans all activities from target discovery
    through to completion of proof-of-concept clinical trials for
    novel therapeutic antibodies. Following proof of concept
    in human clinical trials, programs may be partnered for subsequent
    development, approval and marketing. Both companies
    will contribute their core technologies and expertise to
    the alliance. Galapagos will provide antibody targets implicated
    in bone and joint diseases in addition to its adenoviral
    target discovery platform to discover further targets for
    antibody development. MorphoSys will contribute its HuCAL
    antibody technologies to generate fully human antibodies
    directed against these targets. Under the terms of the agreement,
    Galapagos and MorphoSys will share the research and
    development costs, as well as all future revenues equally.
  6. forum rang 4 marcello106 10 februari 2011 15:01
    Vorig jaar was de uitbreiding van deze alliantie nog een reden om een persbericht de wereld in te sturen.

    www.glpg.com/press/2010/7%27.htm

    Tegenwoordig wordt een uitbreiding gewoon bij de partnerships vermeld?

    www.glpg.com/partnering/partnerships.htm

    “Antibodies with high specificity towards the first target have been generated and are now being tested in disease-specific experiments. In parallel, Galapagos has applied its target discovery platform to identify additional targets for antibody development. The partners have since added another additional antibody targets to the alliance, thereby increasing the total number of programs to five.”

  9. [verwijderd] 18 april 2012 13:44
    De laatste tijd loopt koer van Morphosys op. vandaag naar EUR 22.50
    voreger schommelde de koers rond EUR 18 samen met crucell.

    Het lijkt er op dat dit samenhangt met een op 2 april gestart aandeleninkoop programma.

    vandaag nieuwe commissarissen benoemd:
    MorphoSys Nominates Karin Eastham and Marc Cluzel as New Supervisory Board Members
    .

    April 18, 2012 / 7:30 am, CET

    MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that the Company will nominate Ms. Karin Eastham and Dr. Marc Cluzel as new members of the Supervisory Board at the Company's Annual Shareholder Meeting on Thursday, May 31, 2012. Ms. Eastham and Dr. Cluzel will replace Prof. Dr. Jürgen Drews and Dr. Metin Colpan. Prof. Drews has been a member of MorphoSys AG's Supervisory Board since 1998, while Dr. Colpan joined in 2004.

    "We are delighted to be able to present two highly qualified candidates for MorphoSys's Supervisory Board," commented Dr. Gerald Möller, Chairman of the Supervisory Board of MorphoSys AG. "Karin Eastham and Marc Cluzel both have outstanding track records in our industry and have contributed to the successful performance of several companies over the course of their careers."

    Karin Eastham is an experienced financial executive who currently serves as director on the Corporate Boards of Illumina, Inc., Amylin, Inc., Trius Therapeutics, Inc. and Geron Corporation. From May 2004 to September 2008, she served as Executive Vice President and Chief Operating Officer and as a member of the Board of Trustees of the Burnham Institute for Medical Research, a non-profit corporation engaged in basic biomedical research. From 1999 to 2004, Ms. Eastham served as Senior Vice President, Finance, Chief Financial Officer and Secretary of Diversa Corporation. She previously held similar positions with CombiChem, Inc. and Cytel Corporation. She also held several positions, including Vice President, Finance, at Boehringer Mannheim Diagnostics, from 1976 to 1988. Ms. Eastham received a B.S. and a M.B.A. from Indiana University and is a Certified Public Accountant.

    Dr. Marc Cluzel, an established innovator and leader in the pharmaceutical industry, has more than 20 years of extensive knowledge and experience in Research & Development and product registration in the USA, Europe and Japan. Dr. Cluzel founded C&F consulting in 2011 and serves also as Executive Vice President of Product Development at HÙYÀ Bioscience International, LLC. Dr. Cluzel served as global head of R&D for Sanofi from 2007 to 2011, as Executive Vice President of Research & Development for Sanofi (Formerly Sanofi-Aventis SA) and before 2009 as its Senior Vice President of Science and Medical Affairs. He was also since 2002 chairman and CEO of Sanofi-Synthelabo R&D France then Sanofi-Aventis R&D France. His career began in hospital medical care and gradually transitioned to research at Johns Hopkins University, Baltimore and Guy's Hospital, London. Dr. Cluzel holds both an MD and a PhD from the University of Montpellier, France.
  10. forum rang 4 harvester 17 september 2012 23:02
    Koers morphosys was wat gezakt maar is weer aan het stijgen vandaag ruim 2%.
    Het waarom is mij nog niet duidelijk. Iemand een idee?

    quote:

    grapesharvester schreef op 18 april 2012 13:44:

    De laatste tijd loopt koer van Morphosys op. vandaag naar EUR 22.50
    voreger schommelde de koers rond EUR 18 samen met crucell.

    Het lijkt er op dat dit samenhangt met een op 2 april gestart aandeleninkoop programma.

    vandaag nieuwe commissarissen benoemd:
    MorphoSys Nominates Karin Eastham and Marc Cluzel as New Supervisory Board Members
    .

    April 18, 2012 / 7:30 am, CET

    MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that the Company will nominate Ms. Karin Eastham and Dr. Marc Cluzel as new members of the Supervisory Board at the Company's Annual Shareholder Meeting on Thursday, May 31, 2012. Ms. Eastham and Dr. Cluzel will replace Prof. Dr. Jürgen Drews and Dr. Metin Colpan. Prof. Drews has been a member of MorphoSys AG's Supervisory Board since 1998, while Dr. Colpan joined in 2004.

    "We are delighted to be able to present two highly qualified candidates for MorphoSys's Supervisory Board," commented Dr. Gerald Möller, Chairman of the Supervisory Board of MorphoSys AG. "Karin Eastham and Marc Cluzel both have outstanding track records in our industry and have contributed to the successful performance of several companies over the course of their careers."

    Karin Eastham is an experienced financial executive who currently serves as director on the Corporate Boards of Illumina, Inc., Amylin, Inc., Trius Therapeutics, Inc. and Geron Corporation. From May 2004 to September 2008, she served as Executive Vice President and Chief Operating Officer and as a member of the Board of Trustees of the Burnham Institute for Medical Research, a non-profit corporation engaged in basic biomedical research. From 1999 to 2004, Ms. Eastham served as Senior Vice President, Finance, Chief Financial Officer and Secretary of Diversa Corporation. She previously held similar positions with CombiChem, Inc. and Cytel Corporation. She also held several positions, including Vice President, Finance, at Boehringer Mannheim Diagnostics, from 1976 to 1988. Ms. Eastham received a B.S. and a M.B.A. from Indiana University and is a Certified Public Accountant.

    Dr. Marc Cluzel, an established innovator and leader in the pharmaceutical industry, has more than 20 years of extensive knowledge and experience in Research & Development and product registration in the USA, Europe and Japan. Dr. Cluzel founded C&F consulting in 2011 and serves also as Executive Vice President of Product Development at HÙYÀ Bioscience International, LLC. Dr. Cluzel served as global head of R&D for Sanofi from 2007 to 2011, as Executive Vice President of Research & Development for Sanofi (Formerly Sanofi-Aventis SA) and before 2009 as its Senior Vice President of Science and Medical Affairs. He was also since 2002 chairman and CEO of Sanofi-Synthelabo R&D France then Sanofi-Aventis R&D France. His career began in hospital medical care and gradually transitioned to research at Johns Hopkins University, Baltimore and Guy's Hospital, London. Dr. Cluzel holds both an MD and a PhD from the University of Montpellier, France.

  11. [verwijderd] 17 september 2012 23:39
    Ze werken al samen, voor MorphoSys zou Galapagos wel een mooie overnamekandidaat zijn...
    Denk persoonlijk niet dat Galapagos snel wordt overgenomen,, tenzij het een super-prijs zou zijn.
    De hoofdprijs zie ik nog niet op de proppen komen.
    De markt geeft Galapagos nu een waarde van nog geen 400 miljoen, mochten ze met 2 middelen op de markt komen(bv. 634 en 187) dan zal de marktwaarde waarschijnlijk enkele miljarden zijn.
    Natuurlijk zal er een aantal onderzoeken doodlopend, Galapagos heeft een hoop verschillende onderzoeken lopen, dus de kans op uiteindelijk succes is groot.
    Waarschijnlijk krijg ik hierop reakties, dat ik de risico's niet zie, roze bril en pusher....
  12. harrysnel 17 september 2012 23:50
    Denk dat koers Morphosys vooral profiteert van de voortgang mbt samenwerking Roche op het gebied van Alzheimer:

    www.morphosys.com/pressrelease/morpho...

    Dit valt samen met tegenvallende resultaten van J&J/Pfizer/Elan's bapinezumab en Lilly's solanezumab waardoor het Roche/Morphosys programma op dit moment het verst gevorderd is. Roche heeft onlangs besloten de fase 3 trial uit te breiden en het aantal proefpersonen te verdubbelen waardoor in best case scenario volstaan kan worden met deze test.

    www.morphosys.com/pressrelease/morpho...

    Edit@MoNey: Galapagos is m.i. absoluut niet interessant voor Morphosys. Pipeline van Morphosys is meer dan goed gevuld; er valt eerder te verwachten dat ze hun afdeling Adb Serotec afstoten. Hier wordt wel eens het unieke businessmodel van Galapagos benadrukt maar Morphosys is vergelijkbaar bedrijf. Ook zij kunnen eigen programma's financieren met inkomsten vanuit overig deel van het bedrijf. Galapagos is interessant bedrijf maar zeker niet uniek; ook niet vwb vermeende onderwaardering.
  14. [verwijderd] 18 september 2012 18:13
    quote:

    harrysnel schreef op 17 september 2012 23:50:

    Galapagos is interessant bedrijf maar zeker niet uniek; ook niet vwb vermeende onderwaardering.

    De markt denkt daar toch anders over. Het afgelopen jaar is de koers met 150% gestegen en veel koersdoelen liggen ver boven de huidige koers.

    De markt vindt GLPG dus echt een interessant bedrijf en de meeste analisten vinden GLPG ondergewaardeerd.

    Uniek ben je als je het patent hebt van de JAK1 samenstelling voor RA. Abbott wil daar 1,3 miljard dollar voor neertellen.

    Harrysnel je mening staat haaks op die van de markt en Abbott. Laat ik de markt en Abbott voorlopig maar als waar aanhouden.
  15. [verwijderd] 18 september 2012 19:56
    quote:

    stappa schreef op 18 september 2012 18:13:

    [...]

    De markt denkt daar toch anders over. Het afgelopen jaar is de koers met 150% gestegen en veel koersdoelen liggen ver boven de huidige koers.

    De markt vindt GLPG dus echt een interessant bedrijf en de meeste analisten vinden GLPG ondergewaardeerd.

    Uniek ben je als je het patent hebt van de JAK1 samenstelling voor RA. Abbott wil daar 1,3 miljard dollar voor neertellen.

    Harrysnel je mening staat haaks op die van de markt en Abbott. Laat ik de markt en Abbott voorlopig maar als waar aanhouden.

    Lijkt me verstandig.
  16. [verwijderd] 21 september 2012 09:44
    MorphoSys's MOR103 Antibody Demonstrates Excellent Safety and Efficacy in Rheumatoid Arthritis Patients

    September 20, 2012 / 10:10 pm, CET

    Results from Phase 1b/2a Trial Show Substantial Reduction of RA Symptoms Based on ACR and DAS28 Disease Scores


    Primary and secondary endpoints of the study successfully met
    MOR103 showed excellent safety data at all doses administered
    First anti-GM-CSF antibody to demonstrate proof-of-concept in patients
    ACR20 score of up to 68% at week 4
    Strong onset of therapeutic effect as early as 2 weeks
    Anti-inflammatory effects supported by MRI analysis
    MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced results from the phase 1b/2a clinical trial evaluating its proprietary HuCAL antibody MOR103 in rheumatoid arthritis (RA) patients. The positive data make MOR103 the first anti-GM-CSF antibody to demonstrate clinical efficacy in RA. The results demonstrate the compound's potential to become an important new drug in an area of unmet medical need. MorphoSys will submit a late-breaking abstract for a forthcoming conference to present the clinical trial results before the end of the year.

    "We are very excited by the results of the study," commented Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG. "The ACR20 score ranks amongst the highest seen for a biological compound in RA after four weeks of treatment. The excellent efficacy and safety data we observed underline MOR103's potential to become a first-in-class treatment modality for RA patients, with a novel and differentiated mechanism of action. We expect to present the data at the most relevant medical conference for RA later this year. The quality of the data demonstrates the capabilities of our discovery and development organization and mark a significant step in MorphoSys's strategy to bring innovative drugs to patients."

    The best response was achieved in the 1.0 mg/kg dose cohort with an ACR20 score of 68% at week 4, which was significantly higher than in the control arm (p<0.0001). Of particular importance was the fast onset of action observed: within 2 weeks, up to 40% of patients achieved an ACR20 score. Improvement of DAS28 scores was rapid and significant over the treatment period of the study. MRI scans revealed a reduction of synovitis according to the RAMRIS system at week 4.

    MOR103 was safe and well-tolerated at all doses administered. There were no drug-related serious adverse events. No obvious differences in the adverse event rate between the MOR103 and placebo groups were observed.

    "These are excellent results," commented the principal investigator of the study, Professor Harald Burkhardt, Professor of Rheumatology and Head of the Division of Rheumatology at Frankfurt University. "Considering the short first-in-patient study, MOR103 demonstrated very promising clinical activity and fast onset of action with favorable safety data."

    In the randomized, double-blind, placebo-controlled phase 1b/2a trial in 96 mild to moderate RA patients, MOR103 was administered in four weekly doses of 0.3 mg/kg, 1.0 mg/kg or 1.5 mg/kg. The trial, which was designed to look in particular at the onset of the therapeutic effect, was conducted in 26 centers in Germany, Netherlands, Poland, Bulgaria and Ukraine. The majority of the trial participants were on a stable regimen of disease modifying anti-rheumatic drugs. The primary endpoint of the trial was to determine the safety and tolerability of multiple doses of MOR103 in patients with active RA. Secondary outcome measures were pharmacokinetics, immunogenicity, and the drug's potential to improve clinical signs and symptoms of RA as measured by DAS28, ACR20/50/70 and EULAR response criteria, MRI imaging for synovitis and bone edema as well as patient reported outcomes.

    Based on these compelling data, MorphoSys will now proceed with its plans to seek a commercial partner for further development of the program. In addition to the RA study, MOR103 is currently being evaluated in a phase 1b dose-escalation study in multiple sclerosis. Results of a phase 1 pharmacokinetic study in healthy volunteers to evaluate a subcutaneous formulation of MOR103 will be available shortly.

    tinyurl.com/co52old
  18. harrysnel 21 september 2012 21:55
    quote:

    stappa schreef op 21 september 2012 18:49:

    Tja....met een ACR20 van 68% kunnen ze niet tippen aan de ACR20 van 83% van GLPG 0634. Maar goed MOR103 is dan ook een ander concept. Geen JAK maar anti.

    These are excellent results, commented prof Burkhardt. Waarop ik zeg:
    Die is al snel tevree....
    Nuancering is m.i. op zijn plaats mbt 68 vs 83 procent.

    Webcast van Morphosys: Galapagos werd niet vermeld op de slides maar wel genoemd om resultaten in perspectief te plaatsen. Belangrijk: onderzoek Morphosys onder mild-to-moderate RA patiënten, niet onder moderate-to-severe zoals bij Galapagos. Zie verschil in DAS28 score van deelnemers. Uit eerder onderzoek blijkt dat behaalde ACR20 scores sowieso hoger uitvallen in de door Galapagos onderzochte populatie. Zie slide 11:

    www.morphosys.com/sites/default/files...

    Verder heeft in het Galapagos onderzoek de placebo groep een zeer hoge ACR20 score van 33,3 procent, bij Morphosys is dit 7 procent! Als je corrigeert voor verschil in populatie en placebo dan zijn de gevonden resultaten in het Morphosys onderzoek beter dan die van de Galapagos jak volgens spreker tijdens de Webcast.

    Ik heb niet voldoende kennis om dit te bevestigen maar op mij komt deze redenering geloofwaardig over. Misschien dat kenner (Maxen?Flosz?) dit kan bevestigen.

    Heb overigens long positie in zowel Morphosys als Galapagos.
451 Posts
Pagina: «« 1 2 3 4 5 6 ... 23 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Galapagos meldt fraai succes rond nieuwe therapie: zit er weer muziek in het aandeel?

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Galapagos Nieuws

  1. Kepler Cheuvreux zet Galapagos op verkooplijst
  2. Klinische resultaten Galapagos steunen celtherapie-hypothese
  3. Deutsche Bank verlaagt koersdoel Galapagos
  4. Financials en Shell doen goede zaken op terughoudend Damrak
  5. Galapagos herhaalt cash burn voor 2024
  6. Galapagos benoemt investeerder Nodelman in bestuur
  7. EcoR1 nog groter in Galapagos
  8. EcoR1 groter in Galapagos
  9. FMR LLC kleiner in Galapagos
  10. EcoR1 meldt belang in Galapagos